Mitozantrone (Novantrone - Lederle) is a new cytotoxic drug licensed for the treatment of breast cancer, hepatocellular carcinoma, non-Hodgkin lymphomas and relapsed acute myeloblastic leukaemia in adults. The manufacturer calls it “the key to new opportunities in cancer chemotherapy” with less toxicity than related drugs. Does the evidence support this?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.